Clinical Evaluation of Yiqihuoxue Therapy for the Prevention and Treatment of Periprocedural Myocardial Injury and Angina Associated with PCI

INTERVENTION: Treatment group:In addition to the standard of care (SOC), patients will receive Qixuekang Oral Liquid (30 ml, orally, twice daily).;Control Group:In addition to the standard of care (SOC), patients will receive Qixuekang Oral Liquid placebo (30 ml, orally, twice daily).; CONDITION: Periprocedural Myocardial Injury Associated with PCI PRIMARY OUTCOME: High‐Sensitivity Troponin I(hs‐cTnI)levels;Seattle Angina Questionnaire (SAQ) summary score; SECONDARY OUTCOME: Incidence of Periprocedural Myocardial Injury Associated with PCI;Creatine kinase‐MB (CK‐MB) levels;High‐sensitivity C‐reactive protein (hs‐CRP) levels;Seattle Angina Questionnaire (SAQ) subscale scores;Chest pain Visual Analogue Scale (VAS) score;Canadian Cardiovascular Society (CCS) angina class;Nitroglycerin Withdrawal and Reduction Rate;Traditional Chinese Medicine (TCM) syndrome score;Incidence of major adverse cardiovascular events (MACE); INCLUSION CRITERIA: (1)Age between 40 and 79 years (inclusive); (2)Patients diagnosed with coronary heart disease, presenting with angina symptoms, and scheduled for elective PCI; (3)Normal hs‐cTnI level prior to the procedure; (4)Fulfilling the Traditional Chinese Medicine diagnostic criteria for Qi deficiency and blood stasis syndrome; (5)Voluntarily sign the written informed consent form.